Luke Devey

Company: Quell Therapeutics

Job title: Chief Medical Officer

Seminars:

Exploring Autologous CD-19 CAR-Tregs for Rheumatology to Advance Treatment Development for Unmet Diseases 1:10 pm

Explore the role of the immune system in rheumatoid scleroderma Hear preclinical evidence from Quell Therapeutics on their novel therapy targeting rheumatoid sclerodermaRead more

day: Conference Day One Pink Track P2

Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies 1:40 pm

Expand therapeutic approaches beyond B-cell depletion Highlight safety challenges with depletion in comparison to tolerance with Tregs Explore the long-term biological effects of B-cell depletion and immune reprogramming therapiesRead more

day: Conference Day One Pink Track P2